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Abstract: Introduction: Bladder cancer is the ninth common cause of cancers in both sexes worldwide. Nev-
ertheless, little is known about the descriptive and analytic epidemiology of bladder cancer in Iran. 
The present study aimed to describe the nationwide distribution of death due to bladder cancer in 
Iran. 
Methods: This cross-sectional study used data of bladder cancer cases who were registered in the 
national cancer-registry system by the Ministry of Health and Medical Education during 2001-2007. 
Age-standardized mortality rates due to bladder cancer were presented according to nine geo-
graphic poles across the country. 
Results: The overall mortality rate of bladder cancer (per 100,000 population) was 2.26 in men and 
1.36 in women; while the rates were constantly higher for men across all age groups.  The highest 
and lowest age-standardized mortality rates in provinces (per 100,000 population) belonged to Ma-
zandaran (6.126) and Tehran (1.112), respectively. 
Conclusion: Death from bladder cancer seems to increase by age in Iran, mainly among men. This 
association might be partially due to increased life expectancy, altered high-risk lifestyle behaviors 
and/or improvement in cancer registration system. Information on the distribution of mortality due 
to bladder cancer could be useful for local prevention strategies, where specific profile of commu-
nities and patients is taken into account. 
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1. Introduction
 ancer is one of the major health problems and a 
major cause of the burden of disease worldwide 
(1). In general, cancers are ranked the third cause 
of death following accidents and cardiovascular dis-
eases in Iran (2,3). Similar to many cancers, bladder can-
cer incidence is also influenced by changing in the dis-
tribution of certain risk factors such as tobacco smoking, 
and by dramatic improvement in data registration and 
cancer diagnosis. With 430,000 new cases and 165,000 
deaths worldwide in 2012, bladder cancer is the ninth 
common cause of cancers in both sexes (2). Most cases 
(77%) happen in men. The global mortality rate is 4 per 
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100,000 in men and 1.1 per 100,000 in women (4). 
According to epidemiologic studies bladder cancer inci-
dence is increasing in Iran (3, 4).The variation in inci-
dence and mortality of bladder cancer in different coun-
tries is due to various environmental risk factors and ge-
netic differences. The highest incidence of bladder can-
cer has been reported in Egypt, Europe, North America 
and North Africa (5-7); while the lowest incidence has 
been reported in Asian countries (7). Bladder cancer is 
known as the cancer of developed countries, where the 
age-standardized incidence is 3- 4 times higher in com-
parison to developing countries (8-10). Cigarette and 
opium smoking and occupational exposures are the 
well-established risk factors for development of bladder 
cancer (11).  
Due to limited evidence on morbidity and mortality of 
bladder cancer in Iran, the present study was conducted 
to estimate the mortality pattern of bladder cancer us-




Data of patients in this study was collected from the De-
partment of National registry on Cancer located at the 
Ministry of Health and Medical Education (MOH&ME) in 
Iran during 2001-2007.  In this study, all patients who 
were diagnosed with primary bladder cancer and regis-
tered in MOH&ME were included. The following infor-
mation was collected via a telephone survey by trained 
interviewers after informed consent was sought ver-
bally: survival status, demographic characteristics, age 
of diagnosis, pathological findings, and clinical profile. 
Verbal autopsy was performed for deceased patients on 
one first-degree family member. According to the study 
protocol, three telephone calls within two consecutive 
weeks were considered as sufficient attempt to collect 
the information. We excluded cases whom we call them 
three times within two consecutive weeks and received 
no response. For statistical analysis, age of diagnosis 
was categorized into five groups: less than 50, 51-60, 
61-70 and 71-80, and over 80 years. The pathologic type 
of bladder cancer was dichotomized. Provincial poles 
were categorized based on Universities of Medical Sci-
ences into nine categories including: Mazandaran (Uni-
versities of Mazandaran, Gilan, Golestan, Semnan, Ba-
bol), Shiraz (Universities of Shiraz, Bushehr, Bandar Ab-
bas, Kohgeloyeh, Jahrom, Fesa), Kermanshah (Universi-
ties of Kermanshah, Kordestan, Hamadan, Ilam), Ahvaz 
(Universities of Ahvaz, Lorestan), Tabriz (Universities 
of Tabriz, West-Azarbayejan, Ardabil, Zanjan), Tehran 
(Universities of Tehran, Markazi, Gahzvin, Ghom), Ker-
man (Universities of Kerman, Zahedan, Zabol, Rafsan-
jan), Khorasan (Universities of Khorasan-Razavi, Khora-
san-South, Khorasan-North, Sabzevar, Shahroud, Gona-
bad), and Isfahan (Universities of Isfahan, Yazd, Chahar-
mahal, Kashan).  Mortality rates with 95% Confidence 
Intervals (CI) were calculated according to year of reg-
istration, gender, age group, and provincial pole by in-
serting census results as the denominator. Direct stand-
ardization was performed to estimate age-standardized 
mortality rates across nine provincial poles. P-value less 
than 5% was considered statistically significant. All the 
analyses were done using STATA version 14 (StataCorp. 
2015. Stata Statistical Software: Release 14. College Sta-
tion, TX: StataCorp LP). 
 
3. Result 
16,702 patients with bladder cancer were registered, of 
whom contact information of 7,686 (46%) cases were 
registered. Of these, 3,946 cases (51%) were contacted 
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by the telephone survey, and amongst whom 
information of 3,337 patients (84.5%) was collected. 
554 of 3337 patients (16.6%) were female and 2783 
(83.4%) were male (Table 1). Distribution of age at 
diagnosis showed that by the time of diagnosis, the 
highest and lowest proportion of bladder cancer 
patients were 71-80 (28.2%) and more than 80 (13.5%) 
years old, respectively (Figure 1). Moreover, the highest 
and lowest proportion of bladder cancer cases were 
registered in Isfahan (21.4%) and Kerman (5%) poles, 
respectively (Figure 2). 
The pathology of bladder cancer was TCC-Low Grade in 
2,331 (69.9%) patients, TCC-High Grade in 879 (26.4%) 
patients, Papillary Adenocarcinoma in 33 (1%) patients, 
undifferentiated carcinoma in 18 (0.5%) patients, SCC 
in 48 (1.4%) patients, and other tumors in 28 (0.8%) 
patients. 
Overall, the mortality rate of bladder cancer (per 
100,000 male population) was estimated as 2.26 in men 
and 1.36 in women.  Specifically, the overall mortality 
rates of bladder cancer in males (per 100,000 male 
population) according to the provincial poles were as 
follow: 3.49 in Mazandaran, 2.78 in Shiraz, 2.16 in 
Kermanshah, 2.05 in Ahvaz, 1.50 in Tabriz, 1.80 in 
Tehran, 1.32 in Kerman, 2.13 in Khorasan, and 4.33 in 
Isfahan. Moreover, the mortality rates of bladder cancer 
in females (per 100,000 female population) according to 
provincial poles were as follow: 0.83 in Mazandaran, 
Figure 2:  Distribution of registered bladder cancer patients from the national cancer-registry system during 2001-2007 
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1.16 in Shiraz, 0.54 in Kermanshah, 0.51 in Ahwaz, 0.23 
in Tabriz, 0.46 in Tehran, 0.28 in Kerman, 0.64 in 
Khorasan, and 0.86 in Isfahan. 
Given the estimated mortality rates according to age 
groups and gender, Table-1 shows the results of 
mortality rates in nine provincial poles across Iran. The 
mortality rates were drastically higher in men 
compared to women; the lowest mortality rate in men 
was observed in patients younger than 50 years of age.  
The rates of death due to bladder cancer are shown in 
Table 1. The lowest mortality rate was seen in Tehran 
pole (rate: 0.005, 95%CI: 0.001, 0.011) and the highest 
rate was seen in Mazandaran pole (rate: 0.94, 95%CI: 
0.19, 2.77).  
 The lowest risk of death in men whom their age was 
between 51-60 years old, was reported from Khorasan 
pole (rate: 1.74, 95%CI: 0.35, 5.08) and the highest risk 
of death was reported from Isfahan pole (rate; 5.62, 
95%CI: 2.90, 3.55).   The lowest risk of death in men 
whom their age was between 61-70 years old was 
reported from Tabriz (rate: 1.66, 95%CI: 6.32, 16.85) 
and the highest was reported from Khorasan pole (rate: 
21.01, 95%CI: 13.46, 31.26). The lowest risk of death in 
men whom their age was between 71-80 years old, was 
reported from Tabriz pole (rate: 14.97, 95%CI: 9.01, 
23.37) and the highest was reported from Isfahan pole 
(rate: 56.50, 95%CI: 41.80, 74.68). Finally, the lowest 
risk of death in men older than 80 years old was 
reported from Kerman pole (rate: 28.04, 95%CI: 10.29, 
61.02) and the highest was reported from Ahvaz pole 
(rate: 121.68, 95%CI: 74.34, 187.86) (Table 11). The 
highest and lowest male-to female ratio of death due to 
bladder cancer was observed in patients aged 61-70 
years old (5.99) and less than 50 years (2.63) (Figure 3).      
 
4. Discussion 
 According to the recent reports from the Ministry of 
Health and Medical Education in Iran; the most common 
causes of death in Iran are coronary heart disease, acci-
dents and cancers, respectively (12). Cancer is a major 
public health concern in the world (5). Bladder Cancer 
(BCa) is the most common malignancy of the urinary 
tract mainly in developing countries (12), with annual 
mortality rates ranging from 1–5 deaths per 100,000 
men and 0.5–1.5 deaths per 100,000 women (9).  
Table 1: Crude mortality rates due to bladder cancer according to provincial poles (2001-2007) 
 Mortality rate (per 100,000 population) 
 <50 51-60 61-70 71-80 >80 
Mazandaran 
Male 0. 94 (0. 19, 2.77) 3.91 (1.95, 7.00) 14.58 (9.34, 21.70) 17.55 (13.03,23.13) 52.45 (32.04,80.99) 
Female 0.009 (0.002,0.027) 1.03 (0.212,3.00) 1.79 (0.37,5.24) 2.33 (.93,4.81) 13.23 (4.30,30.88) 
Shiraz 
Male 0.135 (0.036, 0.346) 5.35 (2.67,9.58) 15.75 (9.00,25.57) 54.68 (40.32,72.49) 65.94 (39.71,102.96) 
Female zero occurrence zero occurrence 4.94 (1.60,11.52) 12.50 (5.72,23.72) 10.49 (2.16,30.64) 
Kermanshah 
Male 0.146 (0.030,0.428) 3.20 (1.04,7.46) 17.87 (10.22,29.02) 39.57 (26.08,57.57) 44.54 (23.01, 77.78) 
Female 0.099 (0.012,0.360) 0.617 (0.015, 3.44) zero occurrence 11.95 (4.80,24.62) 18.17 (4.95,46.52) 
Ahvaz 
Male 0.146 (0.03,0.425) 2.19 (0.451, 6.40) 15.39 (7.68,27.54) 50.94 (33.57,74.11) 121.68 (74.34,187.86) 
Female 0.101 (0.012,0.364) 0.71 (0.01, 4.00) 4.32 (0.89,12.62) 18.72 (8.08,36.89) 6.41 (0.162,35.70) 
Tabriz 
Male 0.111 (0.030,0.285) 4.55 (2.35, 7.95) 1.66 (6.32,16.85) 14.97 (9.01,23.37) 31.00 (16.5,53.01) 
Female 0.028 (0.000,0.160) 0.72 (0.087, 2.620) 1.19 (0.14, 4.29) 0.895 (0.02, 4.98) zero occurrence 
Tehran 
Male 0.005 (0.001,0.011) 2.55 (1.46,4.15) 8.98 (6.15,12.68) 28.16 (21.54,36.17) 39.13 (26.21,56.19) 
Female 0.028 (0.003,0.102) 0.16 (.00,0.09) 1.82 (0.66,3.97) 6.62 (3.53,11.32) 12.11 (5.54,22.99) 
Kerman 
Male 0.217 (0.070,0.507) 4.72 (1.73,10.72) 8.35 (3.06,18.16) 20.52 (10.24,36.72) 28.04 (10.29,61.02) 
Female 0.045 (0.001,0.250) 0.801 (0.02, 4.46) zero occurrence 4.67 (0.56-16.86) 11.3 (1.37,40.80) 
Khorasan 
Male 0.233 (0.085,0.507) 1.74 (0.35,5.08) 21.01 (13.46,31.26) 19.90 (11.37,32.31) 39.25 (20.28,68.55) 
Female zero occurrence 1.10 (0.133, 3.97) 4.38 (1.42,10.23) 8.45 (3.10,18.38) 23.63 (8.67,51.43) 
Isfahan 
Male 0.229 (0.084,0.499) 5.62 (2.90,9.81) 20.99 (13.71,30.75) 56.50 (41.80,74.68) 72.16 (46.24,107.34) 
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Up to now, few studies have been conducted on the epi-
demiology of bladder cancer in Iran. Our study was con-
ducted on 3946 registered cases of BCa through the na-
tional cancer registry in Iran.  Out study showed that 
death due to BCa was recorded more frequently among 
males.  The higher mortality rate of BCa in men might be 
due to some masculine high-risk profile such as tobacco 
consumption and exposure to occupational hazards, 
which expose men to higher risk of cancer-related mor-
bidity and mortality. For instance, the results of several 
national surveys in Iran have shown that the prevalence 
of cigarette smoking is higher among men and 0.3% 
among women) (13, 14). In terms of opium consump-
tion, Kerman Province is ranked the fifth in the country 
(12). Since most opium consumers are men, this may ex-
plain the higher risk of death due to bladder cancer in 
men in Kerman compared to the rest of the country. 
This study showed that most bladder cancer tumors 
were superficial and low grade in Iran, which was con-
sistent with the findings of other studies in the world 
(15).  The rate of bladder cancer mortality; however, dif-
fers among provinces that can be attributed to several 
factors such as access to medical care services (10), ed-
ucation, level of income (16), stage and grade of diag-
nosed bladder cancer (17) and age (16). Mahdavifar et 
al. showed that not only there was a positive linear rela-
tionship between the incidence of BCa and Health devel-
opmental index (HDI )(r=0.653, P<0.001),  but also a 
positive linear relationship was revealed between the 
mortality rate of BCa and HDI (r=0.308, P<0.001)(18).  
Pakzad, et al showed that despite the growing incidence 
of bladder cancer in developing countries, there was no 
statistically significant correlation between the inci-
dence rate of bladder cancer and HDI and its compo-
nents in Asia, except for the level of education (16). Our 
study showed that some provinces such as Kerman with 
low HDI has the lowest mortality rate; while mortality 
rate in some other provinces such as Isfahan and Ahvaz 
was the highest. Hence, there seemed to be no apparent 
correlation between HDI and mortality rate due to blad-
der cancer. 
Our study showed that increasing age is associated with 
increased mortality of bladder cancer which was con-
sistent with other studies (16). 
 
5. Conclusion 
According to our results, the mortality rate of bladder 
cancer is increasing with age in Iran. This increasing 
trend may be due to increased prevalence of certain risk 
factors accompanied with economic development, and 
advancement in the national cancer registration system. 
The information on the incidence and mortality of blad-
der cancer, and its distribution 
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